RT Journal Article
SR Electronic
T1 Racial and Ethnic Disparities in the Utilization and Outcomes with WATCHMAN FLX: A SURPASS analysis of the NCDR LAAO Registry
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.06.24306969
DO 10.1101/2024.05.06.24306969
A1 Alli, Oluseun O
A1 Garg, Jalaj
A1 Boursiquot, Brian C.
A1 Kapadia, Samir R
A1 Yeh, Robert W
A1 Price, Matthew J
A1 Piccini, Jonathan P
A1 Nair, Devi G
A1 Hsu, Jonathan C
A1 Gibson, Douglas N
A1 Alloco, TDominic
A1 Christen, Thomas
A1 Sutton, Brad
A1 Freeman, James V
YR 2024
UL http://medrxiv.org/content/early/2024/05/07/2024.05.06.24306969.abstract
AB Background Left atrial appendage occlusion (LAAO) is increasingly used as an alternative to oral anticoagulation for stroke prevention in select patients with atrial fibrillation. Data on outcomes in racial and ethnic minority individuals are limited. This analysis assessed differences in the utilization and outcomes of LAAO by race and ethnicity in a large national registry.Methods This analysis acquired data on WATCHMAN FLX patients from the National Cardiovascular Data Registry (NCDR) LAAO Registry through September 2022. All patients with an attempted WATCHMAN FLX implantation and known race and ethnicity were included. Baseline characteristics and 1 year event rates were compared.Results A total of 97,185 patients were analyzed; 87,339 were White (90%), 3,750 Black (Black/African American 3.9%), and 2,866 Hispanic ([Hispanic/Latinx] 2.9%). Black and Hispanic patients were younger with a higher incidence of prior stroke and significant bleeding compared to White patients. Black and Hispanic patients were treated with LAAO in smaller numbers relative to their proportion of the US population. Rates of procedural success were similar between groups. Though direct oral anticoagulants were prescribed in most patients across the groups, dual and single antiplatelet therapy were prescribed more often in Black patients. Black patients had significantly higher rates of 1-year death and bleeding compared to White and Hispanic patients.Conclusions Patients from racial and ethnic minority groups comprise a disproportionately small fraction of all patients who undergo LAAO. Black and Hispanic patients were younger but had significantly higher comorbidities compared to White patients. Procedural success was similar amongst the groups but Black patients experienced higher rates of death and bleeding at 1 year.What is known There is underutilization of LAAO among racial and ethnic minority patients with AF and there are racial and ethnic differences in periprocedural outcomes.What this study adds In this study from a large US national registry of patients undergoing LAAO, Black patients were younger but had higher baseline comorbidities and experienced higher rates of bleeding at 45 days and 1-year and higher 1-year mortality. Further work is needed to enroll diverse patients into research trials and to provide equitable AF-related access to advanced care and intra- procedural and post-procedural care in US real-world practice.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study did not require IRB approvalI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data is available